BR112021025630A8 - Moléculas novas - Google Patents
Moléculas novasInfo
- Publication number
- BR112021025630A8 BR112021025630A8 BR112021025630A BR112021025630A BR112021025630A8 BR 112021025630 A8 BR112021025630 A8 BR 112021025630A8 BR 112021025630 A BR112021025630 A BR 112021025630A BR 112021025630 A BR112021025630 A BR 112021025630A BR 112021025630 A8 BR112021025630 A8 BR 112021025630A8
- Authority
- BR
- Brazil
- Prior art keywords
- new molecules
- compositions
- compounds
- viral
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
- C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902231A AU2019902231A0 (en) | 2019-06-26 | Novel molecules | |
| AU2019904862A AU2019904862A0 (en) | 2019-12-20 | Novel molecules (2) | |
| PCT/AU2020/050660 WO2020257870A1 (en) | 2019-06-26 | 2020-06-26 | Novel molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021025630A2 BR112021025630A2 (pt) | 2022-02-15 |
| BR112021025630A8 true BR112021025630A8 (pt) | 2023-04-11 |
Family
ID=74059610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025630A BR112021025630A8 (pt) | 2019-06-26 | 2020-06-26 | Moléculas novas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220388950A1 (https=) |
| EP (1) | EP3990428A4 (https=) |
| JP (2) | JP2022539091A (https=) |
| KR (1) | KR20220050873A (https=) |
| CN (2) | CN121045535A (https=) |
| AU (1) | AU2020302839B2 (https=) |
| BR (1) | BR112021025630A8 (https=) |
| CA (1) | CA3142501A1 (https=) |
| IL (1) | IL289266B1 (https=) |
| MX (1) | MX2021015961A (https=) |
| NZ (1) | NZ783377A (https=) |
| WO (1) | WO2020257870A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2618842B1 (en) | 2010-09-22 | 2019-04-24 | Ena Therapeutics Pty Ltd | Novel immunostimulatory method |
| AU2018391325B2 (en) | 2017-12-21 | 2024-07-11 | Axelia Oncology Pty Ltd | Optimised compounds |
| MX2021015961A (es) | 2019-06-26 | 2022-03-22 | Ena Respiratory Pty Ltd | Moleculas novedosas. |
| WO2021237291A1 (en) * | 2020-05-26 | 2021-12-02 | Axelia Oncology Pty Ltd | Treatment of coronavirus |
| JP7744936B2 (ja) | 2020-06-26 | 2025-09-26 | イーナ レスパラトリー ピーティーワイ リミテッド | 分岐脂質化合物 |
| WO2023028661A1 (en) * | 2021-09-02 | 2023-03-09 | Ena Respiratory Pty Ltd | Formulation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ520976A (en) | 1999-11-19 | 2005-01-28 | Csl Ltd | Vaccine compositions |
| HU230847B1 (en) | 2000-05-19 | 2018-08-28 | Corixa Corp | Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds |
| EP1382352A1 (de) | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
| AU2003250586B2 (en) | 2002-08-12 | 2010-09-23 | The Council Of The Queensland Institute Of Medical Research | Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| BR0313101A (pt) | 2002-08-12 | 2005-06-28 | Queensland Inst Med Res | Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso |
| EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
| US20060002941A1 (en) | 2004-01-23 | 2006-01-05 | Vievax Corp. | Compositions comprising immune response altering agents and methods of use |
| WO2005079419A2 (en) | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
| GB0405634D0 (en) | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
| EP2460533A3 (en) | 2004-10-18 | 2014-01-08 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| EP1666056A1 (en) | 2004-12-06 | 2006-06-07 | Bestewil Holding B.V. | Cancer vaccine vesicles |
| US8420102B2 (en) | 2006-03-07 | 2013-04-16 | Vaxinnate Corporation | Compositions that include hemagglutinin |
| NZ556004A (en) | 2004-12-21 | 2010-05-28 | Vaxinnate Corp | Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein |
| CN101151280A (zh) | 2005-02-08 | 2008-03-26 | 昆士兰医学研究学院委员会 | 免疫原性分子 |
| US7560436B2 (en) | 2005-02-22 | 2009-07-14 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
| EP1787660A1 (en) * | 2005-11-22 | 2007-05-23 | GBF Gesellschaft für Biotechnologische Forschung mbH | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions |
| WO2008085549A2 (en) | 2006-07-28 | 2008-07-17 | Board Of Regents Of The University Of Texas System | Compositions and methods for stimulation of lung innate immunity |
| AU2014202674B2 (en) * | 2007-05-04 | 2014-08-14 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
| AU2008310313C1 (en) | 2007-10-09 | 2015-02-12 | Ena Respiratory Pty Ltd | A method of transfection and compositions therefor |
| WO2009137103A2 (en) | 2008-05-09 | 2009-11-12 | Ourth Donald D | Anti-cancer/anti-viral compounds and methods of use |
| US8728465B2 (en) | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| WO2010028246A2 (en) | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| CN103800906B (zh) | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| JP2012523379A (ja) | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| GB0907989D0 (en) | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| EP2338521A1 (en) | 2009-12-28 | 2011-06-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Lipopeptide- and lipoprotein-conjugates and its use |
| EA031379B1 (ru) * | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| EP2618842B1 (en) | 2010-09-22 | 2019-04-24 | Ena Therapeutics Pty Ltd | Novel immunostimulatory method |
| CN113876945A (zh) * | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
| EP3604271A1 (en) | 2013-06-28 | 2020-02-05 | Auckland Uniservices Limited | Peptides for amino acid and peptide conjugates and conjugation process |
| US20170274068A1 (en) | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| JP2016216593A (ja) | 2015-05-19 | 2016-12-22 | 株式会社リコー | 反応材、熱交換器及びケミカルヒートポンプ |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| TW201735952A (zh) * | 2016-02-26 | 2017-10-16 | 瑪格蕾特 安 布萊博 | 胺基酸及肽共軛物以及共軛過程 |
| CN110461351B (zh) * | 2017-03-31 | 2024-03-26 | 艾娜呼吸私人有限公司 | 用tlr2激动剂治疗呼吸道感染 |
| NL2018803B1 (en) * | 2017-04-27 | 2018-11-05 | Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc | Adjuvant compounds |
| EP3676250A4 (en) * | 2017-08-30 | 2021-05-26 | Auckland Uniservices Limited | PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF |
| AU2018391325B2 (en) | 2017-12-21 | 2024-07-11 | Axelia Oncology Pty Ltd | Optimised compounds |
| WO2019119069A1 (en) | 2017-12-21 | 2019-06-27 | Ena Therapeutics Pty Ltd | Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent |
| MX2021015961A (es) * | 2019-06-26 | 2022-03-22 | Ena Respiratory Pty Ltd | Moleculas novedosas. |
| US20220347146A1 (en) | 2019-09-04 | 2022-11-03 | Axelia Oncology Pty Ltd | Cancer treatment |
| AU2020340468A1 (en) | 2019-09-04 | 2022-03-24 | Axelia Oncology Pty Ltd | Cancer immunotherapy |
| WO2021237291A1 (en) | 2020-05-26 | 2021-12-02 | Axelia Oncology Pty Ltd | Treatment of coronavirus |
-
2020
- 2020-06-26 MX MX2021015961A patent/MX2021015961A/es unknown
- 2020-06-26 CN CN202511161213.7A patent/CN121045535A/zh active Pending
- 2020-06-26 EP EP20833003.5A patent/EP3990428A4/en active Pending
- 2020-06-26 JP JP2021577007A patent/JP2022539091A/ja active Pending
- 2020-06-26 US US17/622,451 patent/US20220388950A1/en active Pending
- 2020-06-26 NZ NZ783377A patent/NZ783377A/en unknown
- 2020-06-26 AU AU2020302839A patent/AU2020302839B2/en active Active
- 2020-06-26 BR BR112021025630A patent/BR112021025630A8/pt unknown
- 2020-06-26 CN CN202080046587.3A patent/CN114174260B/zh active Active
- 2020-06-26 WO PCT/AU2020/050660 patent/WO2020257870A1/en not_active Ceased
- 2020-06-26 KR KR1020227000399A patent/KR20220050873A/ko active Pending
- 2020-06-26 CA CA3142501A patent/CA3142501A1/en active Pending
-
2021
- 2021-12-22 IL IL289266A patent/IL289266B1/en unknown
-
2023
- 2023-03-23 US US18/112,091 patent/US12017979B2/en active Active
-
2025
- 2025-04-09 JP JP2025064409A patent/JP2025108536A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021025630A2 (pt) | 2022-02-15 |
| IL289266B1 (en) | 2026-03-01 |
| EP3990428A4 (en) | 2023-07-19 |
| JP2022539091A (ja) | 2022-09-07 |
| KR20220050873A (ko) | 2022-04-25 |
| US12017979B2 (en) | 2024-06-25 |
| US20220388950A1 (en) | 2022-12-08 |
| CN114174260A (zh) | 2022-03-11 |
| CA3142501A1 (en) | 2020-12-30 |
| JP2025108536A (ja) | 2025-07-23 |
| EP3990428A1 (en) | 2022-05-04 |
| AU2020302839B2 (en) | 2025-08-14 |
| MX2021015961A (es) | 2022-03-22 |
| NZ783377A (en) | 2026-03-27 |
| IL289266A (en) | 2022-02-01 |
| AU2020302839A1 (en) | 2022-01-20 |
| US20230257345A1 (en) | 2023-08-17 |
| WO2020257870A1 (en) | 2020-12-30 |
| CN114174260B (zh) | 2025-09-05 |
| CN121045535A (zh) | 2025-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021025630A8 (pt) | Moléculas novas | |
| BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
| CL2018002826A1 (es) | Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| BR112015028879A2 (pt) | derivados heterocíclicos | |
| CL2020001147A1 (es) | Compuestos antibacterianos | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| BR112017020935A2 (pt) | ?compostos, composição farmacêutica e conjunto? | |
| MX2018001075A (es) | Agentes terapeuticos y profilacticos antibacterianos. | |
| BR112019003427A2 (pt) | compostos antibióticos | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| MX2023009681A (es) | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. | |
| EP3700547A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR LIBERIBACTER DISEASES AND OTHER BACTERIAL DISEASES | |
| CA3010327A1 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
| BR112019006887A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias | |
| BR112019027387A8 (pt) | Composições imunogênicas | |
| CL2018000228A1 (es) | Nuevo antibiótico efectivo de aminoglucósido para bacterias resistentes a múltiples fármacos. | |
| BR112017023359A2 (pt) | ?compostos, composições farmacêuticas e kits? | |
| MX392976B (es) | Composiciones que comprenden cepas bacterianas. | |
| CO2023016983A2 (es) | Cepas bacterianas que tienen actividad fungicida, composiciones que las comprenden y uso de estas | |
| BR112016029619A2 (pt) | novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas | |
| EP3925961A4 (en) | Mitochondria-targeting compound and composition comprising same for treating or preventing aging-related diseases | |
| CO2023007878A2 (es) | Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes | |
| EP4121084A4 (en) | COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY TRACT INFECTION AND THEIR USES | |
| BR112017009504A2 (pt) | métodos para tratar e para curar uma infecção por hcv, e, composição farmacêutica. | |
| BR112017009501A2 (pt) | método para tratar uma infecção por hcv, método para curar uma infecção por hcv, e, composição farmacêutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ENA RESPIRATORY PTY LTD (AU) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |